|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.70 USD | +0.20% |
|
-0.40% | +58.74% |
| May. 26 | Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion | MT |
| May. 20 | Eli Lilly Buys Engage Biologics for Up to $202 Million | DJ |
Company Valuation: Centessa Pharmaceuticals plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,012 | 293.2 | 777.1 | 2,208 | 3,653 | 6,143 | - | - |
| Change | - | -71.03% | 165.01% | 184.18% | 65.43% | 68.14% | - | - |
| Enterprise Value (EV) | 492.9 | -30.6 | 596.3 | 1,835 | 3,469 | 6,143 | 6,143 | 6,143 |
| Change | - | -106.21% | 2,048.91% | 207.77% | 89.02% | 77.08% | 0% | 0% |
| P/E ratio | - | -1.34x | -5.07x | -8.13x | -17.1x | -25.4x | -21.5x | -30.1x |
| PBR | 2.06x | 0.87x | 3.33x | 5.53x | 7.08x | - | - | - |
| PEG | - | - | 0.2x | -0.3x | 0.6x | -3.71x | -1.2x | 1.1x |
| Capitalization / Revenue | - | - | 113x | - | 244x | - | 338x | 39.3x |
| EV / Revenue | - | - | 0x | - | 0x | - | 338x | 39.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | 0x | -0x | -0x | -0x | -24x | -21.6x | -30.3x |
| EV / FCF | - | - | -0x | -0x | -0x | -26.8x | -21.7x | -25x |
| FCF Yield | - | - | -20.7% | -6.43% | -5.32% | -3.74% | -4.62% | -3.99% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | -2.31 | -1.57 | -2.06 | -1.46 | -1.56 | -1.845 | -1.321 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | 6.853 | - | 15 | - | 18.18 | 156.1 |
| EBITDA | -374 | -212.1 | -170.5 | -200.1 | -200.1 | - | - | - |
| EBIT 1 | -374.1 | -212.3 | -171.3 | -201.1 | -207.7 | -256.1 | -284.5 | -202.8 |
| Net income 1 | - | -216.2 | -151.1 | -235.8 | -197.5 | -248 | -276.6 | -203.1 |
| Net Debt | -519.4 | -323.8 | -180.8 | -373.2 | -184.5 | - | - | - |
| Reference price 2 | 11.26 | 3.10 | 7.96 | 16.75 | 25.01 | 39.70 | 39.70 | 39.70 |
| Nbr of stocks (in thousands) | 89,901 | 94,596 | 97,629 | 131,845 | 146,076 | 154,729 | - | - |
| Announcement Date | 3/30/22 | 3/30/23 | 3/28/24 | 3/24/25 | 3/31/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -25.45x | - | - | - | 6.14B | |
| 29.54x | 5.24x | 16.25x | 1.11% | 43.01B | |
| -18.63x | 288.33x | -16.9x | -.--% | 31.57B | |
| 22.28x | 2.56x | 11.07x | -.--% | 30.66B | |
| 40.4x | 4.02x | 25.75x | -.--% | 30.11B | |
| 26.94x | 6.97x | 17.95x | 0.45% | 22.55B | |
| 22.56x | 1.95x | 8.6x | 1.18% | 13.16B | |
| 26.66x | 4.26x | 19.41x | -.--% | 13.08B | |
| -20.53x | 13.4x | -19.95x | -.--% | 12.15B | |
| Average | 11.53x | 40.84x | 7.77x | 0.34% | 22.49B | |
| Weighted average by Cap. | 16.94x | 50.59x | 9.22x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CNTA Stock
- Valuation Centessa Pharmaceuticals plc
Select your edition
All financial news and data tailored to specific country editions
